The GLP-1 Wave: How Weight-Loss Drugs Could Reshape Global Health by 2030

Key figures (as of October 2026)

A new class at global scale

GLP-1 medicines mimic a gut hormone that regulates appetite and blood sugar. First used for type 2 diabetes, they are now widely prescribed for obesity. Uptake has been rapid. Worldwide revenue from the two leading tirzepatide brands, one for diabetes and one for weight management, reached USD 36.5 billion in 2025, against USD 16.5 billion in 2024. In the first nine months of 2026 the same brands brought in USD 43.8 billion, already more than in all of 2025. Across their maker's whole business, third-quarter volumes rose 53% and realised prices fell 15%, both driven mainly by these two brands, a sign that more patients are being treated at lower unit cost.

In December 2025, the global health authority issued its first guideline on GLP-1 therapies for obesity. It conditionally recommends their long-term use by adults, excluding pregnant women, together with healthy diets, physical activity and professional support. The recommendation is conditional because long-term data, costs and health-system readiness are still developing. In September 2025, GLP-1 therapies were also added to the global essential medicines list for type 2 diabetes in high-risk groups.

From injections to pills

Oral versions are widening choice. The first GLP-1 pill for weight management, a once-daily 25 mg oral semaglutide, was approved in the United States on 22 December 2025 and launched on 5 January 2026. It passed more than 3 million prescriptions within about five months, the strongest volume launch for a GLP-1 in that market. A second pill, orforglipron, a small molecule that can be taken at any time of day without food or water restrictions, was approved on 1 April 2026, 50 days after filing. The second pill's US self-pay price starts at USD 149 a month for the lowest dose.

The pills are spreading internationally. The UAE launched the oral semaglutide weight-management pill in June 2026, the first market outside the United States to do so.

Patents, generics and prices

Generic semaglutide is now allowed in several large markets. Generics became legal in Canada on 5 January 2026, and the first two were approved in April and May. In India, China and Brazil the patent lapsed on 20 March 2026. India saw at least 16 generic versions within two days, at prices 70 to 90% below the originator brands, with monthly costs starting at about 1,300 rupees. In Canada, the first widely available generic was priced at less than a third of the brand's wholesale price. Brazil approved its first locally made semaglutide pen in May 2026 from a plant able to make up to 40 million pens a year. China had approved no generic as of October 2026.

Building the supply

Manufacturers are investing heavily. One leading producer has committed more than USD 50 billion to new US manufacturing since 2020 across 10 new sites, including medicine-ingredient and injectable plants. The other leading producer acquired three fill-and-finish sites in Italy, Belgium and the United States in a transaction completed in December 2024. New generic makers in India and Brazil are adding further capacity, and Indian producers have begun exporting to other markets.

Evidence on chronic disease

The case for wider use rests on outcomes beyond weight. In a large trial of adults with overweight or obesity and existing heart disease, but no diabetes, weekly semaglutide cut major cardiovascular events by 20% against placebo. In adults with type 2 diabetes and chronic kidney disease, it reduced major kidney-disease events by 24%. In 2026, tirzepatide also gained US approval to reduce cardiovascular risk in adults with type 2 diabetes.

The scale of need is large. Obesity was associated with 3.7 million deaths worldwide in 2024, and 2.6 billion adults, 45% of all adults, were overweight. Among children and adolescents aged 5 to 19, obesity rose from 2% in 1990 to 8% in 2024.

Scenarios: 2026 revenue of the leading tirzepatide brands

Resolution rule: the combined worldwide revenue of the two tirzepatide brands for full-year 2026, as published in their maker's fourth-quarter 2026 results, expected in early 2027. The figure is taken in USD millions as reported, rounded half up to the nearest whole million if it carries decimals. The five ranges are mutually exclusive and cover every outcome: below USD 59.0 billion; USD 59.0 to 60.5 billion; above USD 60.5 up to 62.0 billion; above USD 62.0 up to 64.0 billion; and above USD 64.0 billion. Values exactly on an edge are assigned as follows: exactly USD 59.0 and 60.5 billion fall in the second band, exactly USD 62.0 billion in the third band and exactly USD 64.0 billion in the fourth band. Nine-month revenue was USD 43.8 billion and third-quarter revenue USD 16.1 billion. If the full-year 2026 revenue of the two brands has not been published by 31 December 2027, the forecast is withdrawn. Probabilities are the Centre's analytical estimates. The forecast is scored with the multi-category Brier score and the ranked probability score, as the bands are ordered.

Scenarios revised on 30 October 2026 to a finer split.

What to watch

1. Early 2027 results: the full-year 2026 figures that resolve the scenarios.
2. Generic approvals: further decisions in Canada and Brazil, and whether China approves its first generic.
3. Oral uptake: weekly prescriptions for the two pills and new country launches.
4. Coverage decisions: public and insurer reimbursement for obesity treatment.
5. New outcome trials: results on heart, kidney and other chronic conditions.

Figures as of October 2026. Probabilities are analytical estimates by the Ghaf Centre for Studies & Research. This study is not medical advice.